Drug

Dexrazoxane

Regulatory activity · MHRA

Emerging researchLate-stage development

Also known as Dextrorazoxane, Totect, Zinecard, Dexrazoxan+6 more

Dextrorazoxane, Totect, Zinecard, Dexrazoxan, Dexrazoxano, (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione, (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane, 2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI), 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI), Dexrazoxanum.

RxNorm42736 ChEMBLCHEMBL1738UNII048L81261F

Research papers

Active clinical trials

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Clinical trial2026-07-16Results expected Q4 2026 · ClinicalTrials.gov

Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment

Clinical trial2026-06-30Results posted · ClinicalTrials.gov

A Randomized Study of Dexrazoxane or Liposomal Doxorubicin in Newly Diagnosed Diffuse Large B-cell Lymphoma at High Risk for Heart Failure Events: the CARDIOPROTECT Trial

Clinical trial2026-06-17Results expected Q4 2030 · ClinicalTrials.gov

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Clinical trial2026-06-17Results expected Q4 2026 · ClinicalTrials.gov

A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma

Clinical trial2026-06-02Results posted · ClinicalTrials.gov

Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)

Clinical trial2026-05-05Results expected Q1 2029 · ClinicalTrials.gov

A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Clinical trial2026-04-17Results expected Q2 2027 · ClinicalTrials.gov

Dexrazoxane for the Reduction of Haemorrhagic Myocardial Infarction in STEMI: A Double-Blind, Placebo-Controlled, Sequential-Cohort Phase IIa Trial

Clinical trial2026-03-16Completed · ClinicalTrials.gov

A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies

Clinical trial2026-03-12Results expected Q3 2028 · ClinicalTrials.gov

A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma

Clinical trial2026-01-23Results posted · ClinicalTrials.gov

Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane (PHOENIX Study): dose response and time course of dexrazoxane-induced degradation of topoisomerase 2b.

Research2025-05-02Cardio-oncology (London, England)

Drug Safety Update: Dexrazoxane (Cardioxane): restriction of use

Regulatory2014-12-11MHRA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Dexrazoxane

Aliases & brands

DextrorazoxaneTotectZinecardDexrazoxanDexrazoxano(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione(+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane2, 6-Piperazinedione, 4,4'-propylenedi-, (P)- (8CI)2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI)Dexrazoxanum

RxNorm CUI

42736

ChEMBL ID

CHEMBL1738

UNII

048L81261F

Regulatory jurisdictions

mhra

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities

MHRA

Total events

mhraMedicines and Healthcare products Regulatory Agency· 1 event

2014-12-11Safety communicationSafety

Drug Safety Update: Dexrazoxane (Cardioxane): restriction of use

Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).